Bronchiectasis (BE) is the third most common lung condition in the UK, yet it is often considered a ‘hidden’ disease due to limited public awareness, investment, and research

Researchers now hope to change that by exploring whether three existing anti-inflammatory drugs could be repurposed to treat bronchiectasis. 

Patients from across the UK will participate by receiving one of three trial drugs. Over the span of a month, they’ll be closely monitored at dedicated trial sites to assess whether the treatment successfully reduces lung inflammation

 James Chalmers, Professor of Respiratory Research at the University of Dundee is the lead for this trial, which is funded by the not-for-profit charity Life Arc.

The trial is being sponsored by the University of Dundee and NHS Tayside and  is being managed by the Tayside Clinical Trials Unit.